MARKET

SPHS

SPHS

Sophiris Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6558
-0.0055
-0.83%
After Hours: 0.6650 +0.0092 +1.40% 19:42 01/17 EST
OPEN
0.6450
PREV CLOSE
0.6613
HIGH
0.7000
LOW
0.6400
VOLUME
386.70K
TURNOVER
--
52 WEEK HIGH
1.350
52 WEEK LOW
0.3301
MARKET CAP
22.61M
P/E (TTM)
182.17
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SPHS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SPHS News

  • The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
  • Benzinga.12/24/2019 12:24
  • The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
  • Benzinga.12/06/2019 12:39
  • SPHS: Single Phase 3 Clinical Trial Planned for Topsalysin in Localized Prostate Cancer
  • Zacks Small Cap Research.11/18/2019 11:20
  • Sophiris Bio files for equity offering
  • seekingalpha.11/13/2019 16:53

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About SPHS

Sophiris Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing products for the treatment of urological diseases. The Company is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer. Topsalysin, a genetically modified recombinant protein, is delivered through ultrasound-guided injection directly into the prostate. This membrane-disrupting protein is selectively activated by enzymatically active prostate specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. This method of administration limits the circulation of the drug in the body. The Company has completed Phase III clinical trials of topsalysin.
More

Webull offers Sophiris Bio Inc (SPHS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.